论文部分内容阅读
脂球蛋白-A(Fatuin-A,α-赫曼-舒密特糖蛋白)是在肝内合成并分泌入血的一种蛋白,能与胰岛素受体结合因而抑制胰岛素信号。在人高水平Fatuin-A常伴随高TG、LDL-C、BMI与IR和糖尿病,且与血Ca++和磷形成复合物增加其溶解性,因而抑制动脉钙沉积。Fatuin-A敲除鼠的IS和异位钙化两者都改善。但人Fatuin-A与心血管病的关系则知之甚少。就我们所知仅有在社区无肾脏疾病的人群中研究Fatuin-A与脑血管疾病(CVD)关系。在EPIC-potsdn研究高水平的Fatuin-A伴随心肌梗死和卒中而与终末期肾病无关。作者最近报告Fatuin-A合并T2DM患者CVD死亡的风险(P=0.003),参加Rancho Ber-
Fatuin-A (α-Hermann-Schmidt glycoprotein) is a protein that is synthesized in the liver and secreted into the blood, which binds to the insulin receptor and thus inhibits insulin signaling. High levels of human Fatuin-A are often accompanied by high TG, LDL-C, BMI and IR, and diabetes mellitus, and form complexes with blood Ca ++ and phosphorus to increase their solubility, thus inhibiting arterial calcium deposition. Fatuin-A knockout mice both improved IS and ectopic calcification. However, the relationship between human Fatuin-A and cardiovascular disease is poorly understood. To investigate the relationship between Fatuin-A and cerebrovascular disease (CVD) in the population as we know only in the community without kidney disease. In the EPIC-potsdn study of high levels of Fatuin-A with myocardial infarction and stroke has nothing to do with end-stage renal disease. The authors recently reported the risk of CVD death in patients with Fatuin-A with T2DM (P = 0.003), Rancho Ber-